
iSTAR Medical
Stage
Project Finance | AliveTotal Raised
$120.6MLast Raised
$60M | 6 mos agoAbout iSTAR Medical
iSTAR Medical is a private, clinical-stage, medical technology company focused on the development of ophthalmic implants for glaucoma. iSTAR Medical's MIGS device, MINIjectTM, provides a safe, effective and sustainable solution to significantly reduce IOP by enhancing aqueous humor outflow from the anterior chamber to the supraciliary space.
iSTAR Medical's Product Videos

Compete with iSTAR Medical?
Ensure that your company and products are accurately represented on our platform.
iSTAR Medical's Products & Differentiators
MINIject
A minimally invasive glaucoma surgery device
Expert Collections containing iSTAR Medical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
iSTAR Medical is included in 2 Expert Collections, including Medical Devices.
Medical Devices
8,592 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,901 items
iSTAR Medical Patents
iSTAR Medical has filed 2 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/27/2012 | 1/6/2015 | Diseases of the eye and adnexa, Ophthalmology, Glaucoma, Eye surgery, Sensors | Grant |
Application Date | 4/27/2012 |
---|---|
Grant Date | 1/6/2015 |
Title | |
Related Topics | Diseases of the eye and adnexa, Ophthalmology, Glaucoma, Eye surgery, Sensors |
Status | Grant |
Latest iSTAR Medical News
Dec 4, 2022
The post iSTAR Medical Expands Commercial Rollout of MINIject with First Surgeries in Sweden and Norway appeared first on NS Medical Devices.
iSTAR Medical Frequently Asked Questions (FAQ)
Where is iSTAR Medical's headquarters?
iSTAR Medical's headquarters is located at Avenue Sabin, 6, Wavre.
What is iSTAR Medical's latest funding round?
iSTAR Medical's latest funding round is Project Finance.
How much did iSTAR Medical raise?
iSTAR Medical raised a total of $120.6M.
Who are the investors of iSTAR Medical?
Investors of iSTAR Medical include AbbVie, European Investment Bank, Capricorn Partners, Societe Regionale d'Investissement de Wallonie, La Societe Federale de Participations et d'Investissement and 11 more.
Who are iSTAR Medical's competitors?
Competitors of iSTAR Medical include Ivantis and 1 more.
What products does iSTAR Medical offer?
iSTAR Medical's products include MINIject.
Compare iSTAR Medical to Competitors

Implandata Ophthalmic Products offers the EYEMATE system to empower people to take control of glaucoma – anytime and anywhere. EYEMATE is an AI-powered, cloud-based, data-centric platform for 24/7/365 monitoring and predictive modeling of disease progression. EYEMATE's data analytics combine IOP with other vital parameters to enable personalized therapies. For people with glaucoma, this means improved quality of life and peace of mind. For eye doctors, this means improved patient care at a significantly lower cost.
CytImmune Sciences is a clinical stage nanomedicine company with a core focus on the discovery, development and commercialization of multifunctional, tumor-targeted therapies.
Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop pharmaceutical treatments for degenerative ocular diseases. The company are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While the company's drug platform is being tested on the company's lead indication, cataract; the company are also in clinical trials for glaucoma and asteroid hyalosis.
ENTRA Pharmaceuticals is a specialty pharmaceutical company developing therapies and improving existing treatments in areas with high unmet medical needs. In addition to the company's technology platform, ENTRA possesses strong expertise in preclinical and clinical drug development and commercialization.
Relevare Pharmaceuticals, formerly CNSBio, is a specialty pharmaceutical company focused on the development of novel therapies to treat chronic and acute pain. Relevare Pharmaceuticals exciting clinical-stage pipeline is comprised of programs that combine or reposition drugs known to be active at CNS targets that modulate pain perception and transmission, and for which there is strong safety evidence in humans. In April 2010, CNSBio rebranded to Relevare Pharmaceuticals.
KeyNeurotek Pharmaceuticals is a clinical stage small molecule company focused on autoimmune and CNS diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.